high frequency episodic migraine
Neurology · 2022–2022
2decisions
2medicines
1carried consumer input
30individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| galcanezumab Treatment of patients with high frequency episodic migraine (8 to <15 migraine headache days per month) who have an inadequate response, intolerance, or… | Mar 2022 | Recommended with restriction | 30 individuals Migraine Australia |
| fremanezumab Treatment of high frequency episodic migraine (HFEM) in patients with inadequate response, intolerance, or contraindication to at least three prophylactic… | Nov 2022 | Recommended with restriction | none received |
Who spoke
Migraine Australia
What the PBS pays
$128M in government benefit over 2024–25, across 232,381 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| fremanezumab | $80M |
| galcanezumab | $48.2M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.